Top

Current Neurology and Neuroscience Reports

Published in:

17-07-2024 | Cluster Headache | Review

Managing Cluster Headache in Patients with Medical, Psychiatric, and Surgical Comorbidities

Authors: Mark J. Burish, Alexander B. Guirguis, Emmanuelle A. D. Schindler

Published in: Current Neurology and Neuroscience Reports | Issue 9/2024

Abstract

Purpose of Review

What should a provider know about medications and other treatments in patients with cluster headache who have medical, psychiatric, and surgical comorbidities? What conversations should providers have with patients about living with and managing cluster headache?

Recent Findings

While the number of treatments used in cluster headache is relatively small, numerous considerations were identified related to managing patients with comorbidities. Many of these touch on cardiac, cardiovascular, and cerebrovascular health, but full histories are needed to guide safe and effective treatment.

Summary

Both older and newer treatments may be contraindicated in certain patients with cluster headache or should be considered carefully. In addition to incorporating medical, psychiatric, and surgical histories in the management plan, collaboration with other providers may be beneficial. Providers should also inquire about patient practices and discuss participation in clinical trials that might be a good fit for the individual.

Lund N, Petersen A, Snoer A, Jensen RH, Barloese M. Cluster headache is associated with unhealthy lifestyle and lifestyle-related comorbid diseases: results from the Danish cluster Headache Survey. Cephalalgia: Int J Headache. 2019;39(2):254–63. https://doi.org/10.1177/0333102418784751.CrossRef

Choong CK, Ford JH, Nyhuis AW, Joshi SG, Robinson RL, Aurora SK, et al. Clinical characteristics and treatment patterns among patients diagnosed with cluster headache in U.S. Healthcare Claims Data. Headache. 2017;57(9):1359–74. https://doi.org/10.1111/head.13127.CrossRefPubMedPubMedCentral

Robbins MS, Starling AJ, Pringsheim TM, Becker WJ, Schwedt TJ. Treatment of Cluster Headache: the American Headache Society evidence-based guidelines. Headache. 2016;56(7):1093–106. https://doi.org/10.1111/head.12866.CrossRefPubMed

May A, Evers S, Goadsby PJ, Leone M, Manzoni GC, Pascual J, et al. European Academy of Neurology guidelines on the treatment of cluster headache. Eur J Neurol. 2023;30(10):2955–79. https://doi.org/10.1111/ene.15956.CrossRefPubMed

Elbadawi ASA, Albalawi AFA, Alghannami AK, Alsuhaymi FS, Alruwaili AM, Almaleki FA, et al. Cluster headache and Associated Risk factors: a systemic review and Meta-analysis. Cureus. 2021;13(11):e19294. https://doi.org/10.7759/cureus.19294.CrossRefPubMedPubMedCentral

Rozen TD. Cluster headache clinical phenotypes: Tobacco Nonexposed (never smoker and no parental secondary smoke exposure as a child) versus Tobacco-Exposed: results from the United States Cluster Headache Survey. Headache. 2018;58(5):688–99. https://doi.org/10.1111/head.13295.CrossRefPubMed

Rozen TD. Linking cigarette Smoking/Tobacco exposure and cluster headache: a Pathogenesis Theory. Headache. 2018;58(7):1096–112. https://doi.org/10.1111/head.13338.CrossRefPubMed

Schindler EAD, Wright DA, Weil MJ, Gottschalk CH, Pittman BP, Sico JJ. Survey Analysis of the Use, Effectiveness, and patient-reported tolerability of Inhaled Oxygen compared with Injectable Sumatriptan for the Acute treatment of Cluster Headache. Headache. 2018;58(10):1568–78. https://doi.org/10.1111/head.13405.CrossRefPubMed

Abdo WF, Heunks LM. Oxygen-induced hypercapnia in COPD: myths and facts. Crit Care. 2012;16(5):323. https://doi.org/10.1186/cc11475.CrossRefPubMedPubMedCentral

10.

Cohen AS, Matharu MS, Goadsby PJ. Electrocardiographic abnormalities in patients with cluster headache on verapamil therapy. Neurology. 2007;69(7):668–75. https://doi.org/10.1212/01.wnl.0000267319.18123.d3.CrossRefPubMed

11.

Lanteri-Minet M, Silhol F, Piano V, Donnet A. Cardiac safety in cluster headache patients using the very high dose of verapamil (>/=720 mg/day). J Headache Pain. 2011;12(2):173–6. https://doi.org/10.1007/s10194-010-0289-x.CrossRefPubMedPubMedCentral

12.

Wei DY, Goadsby PJ. Cluster headache pathophysiology - insights from current and emerging treatments. Nat Rev Neurol. 2021;17(5):308–24. https://doi.org/10.1038/s41582-021-00477-w.CrossRefPubMed

13.

Pachchipulusu VK, Paudel Y, Patel A, Najam B, Desai HN, Illango J, et al. Efficacy of Adenosine Versus Verapamil in terminating Acute attacks of paroxysmal supraventricular tachycardia: a systematic review. Cureus. 2023;15(9):e45946. https://doi.org/10.7759/cureus.45946.CrossRefPubMedPubMedCentral

14.

Schindler EAD, Burish MJ. Recent advances in the diagnosis and management of cluster headache. BMJ. 2022;376:e059577. https://doi.org/10.1136/bmj-2020-059577.CrossRefPubMed

15.

Silberstein SD, Mechtler LL, Kudrow DB, Calhoun AH, McClure C, Saper JR, et al. Non-invasive vagus nerve stimulation for the ACute treatment of Cluster Headache: findings from the Randomized, Double-Blind, sham-controlled ACT1 study. Headache. 2016;56(8):1317–32. https://doi.org/10.1111/head.12896.CrossRefPubMedPubMedCentral

16.

Goadsby PJ, de Coo IF, Silver N, Tyagi A, Ahmed F, Gaul C, et al. Non-invasive vagus nerve stimulation for the acute treatment of episodic and chronic cluster headache: a randomized, double-blind, sham-controlled ACT2 study. Cephalalgia: Int J Headache. 2018;38(5):959–69. https://doi.org/10.1177/0333102417744362.CrossRef

17.

Johnson RL, Wilson CG. A review of vagus nerve stimulation as a therapeutic intervention. J Inflamm Res. 2018;11:203–13. https://doi.org/10.2147/JIR.S163248.CrossRefPubMedPubMedCentral

18.

Administration TUSFaD. IMITREX (sumatriptan) Label. 2021.

19.

Saely S, Croteau D, Jawidzik L, Brinker A, Kortepeter C. Hypertension: a new safety risk for patients treated with erenumab. Headache. 2021;61(1):202–8. https://doi.org/10.1111/head.14051.CrossRefPubMed

20.

Muñoz-Vendrell A, Campoy S, Caronna E, Alpuente A, Torres-Ferrus M, Nieves Castellanos C, et al. Effectiveness and safety of anti-CGRP monoclonal antibodies in patients over 65 years: a real-life multicentre analysis of 162 patients. J Headache Pain. 2023;24(1):63. https://doi.org/10.1186/s10194-023-01585-2.CrossRefPubMedPubMedCentral

21.

Guerzoni S, Castro FL, Brovia D, Baraldi C, Pani L. Evaluation of the risk of hypertension in patients treated with anti-CGRP monoclonal antibodies in a real-life study. Neurol Sciences: Official J Italian Neurol Soc Italian Soc Clin Neurophysiol. 2024;45(4):1661–8. https://doi.org/10.1007/s10072-023-07167-z.CrossRef

22.

Láinez MJA, Schoenen J, Stroud C, Bardos J, Bangs M, Kemmer P, et al. Tolerability and safety of galcanezumab in patients with chronic cluster headache with up to 15 months of galcanezumab treatment. Headache. 2022;62(1):65–77. https://doi.org/10.1111/head.14234.CrossRefPubMed

23.

Tfelt-Hansen P, Tfelt-Hansen J. Verapamil for cluster headache. Clinical pharmacology and possible mode of action. Headache. 2009;49(1):117–25. https://doi.org/10.1111/j.1526-4610.2008.01298.x.CrossRefPubMed

24.

Joshi S, Rizzoli P, Loder E. The comorbidity burden of patients with cluster headache: a population-based study. J Headache Pain. 2017;18(1):76. https://doi.org/10.1186/s10194-017-0785-3.CrossRefPubMedPubMedCentral

25.

Petersen CL, Hougaard A, Gaist D, Hallas J. Risk of stroke and myocardial infarction among initiators of triptans. JAMA Neurol. 2024;81(3):248–54. https://doi.org/10.1001/jamaneurol.2023.5549.CrossRefPubMed

26.

Ghanshani S, Chen C, Lin B, Duan L, Shen YA, Lee MS. Risk of Acute Myocardial Infarction, Heart failure, and death in Migraine patients treated with triptans. Headache. 2020;60(10):2166–75. https://doi.org/10.1111/head.13959.CrossRefPubMed

27.

Roberto G, Raschi E, Piccinni C, Conti V, Vignatelli L, D’Alessandro R, et al. Adverse cardiovascular events associated with triptans and ergotamines for treatment of migraine: systematic review of observational studies. Cephalalgia: Int J Headache. 2015;35(2):118–31. https://doi.org/10.1177/0333102414550416.CrossRef

28.

MacIntyre PD, Bhargava B, Hogg KJ, Gemmill JD, Hillis WS. Effect of subcutaneous sumatriptan, a selective 5HT1 agonist, on the systemic, pulmonary, and coronary circulation. Circulation. 1993;87(2):401–5. https://doi.org/10.1161/01.cir.87.2.401.CrossRefPubMed

29.

Rubio-Beltrán E, Labastida-Ramírez A, Haanes KA, van den Bogaerdt A, Bogers AJ, Dirven C, et al. Characterisation of vasodilatory responses in the presence of the CGRP receptor antibody erenumab in human isolated arteries. Cephalalgia: Int J Headache. 2019;39(14):1735–44. https://doi.org/10.1177/0333102419863027.CrossRef

30.

Depre C, Antalik L, Starling A, Koren M, Eisele O, Lenz RA, et al. A Randomized, Double-Blind, placebo-controlled study to evaluate the Effect of Erenumab on Exercise Time during a Treadmill Test in patients with stable angina. Headache. 2018;58(5):715–23. https://doi.org/10.1111/head.13316.CrossRefPubMedPubMedCentral

31.

Diener HC. The risks or Lack Thereof of Migraine treatments in Vascular Disease. Headache. 2020;60(3):649–53. https://doi.org/10.1111/head.13749.CrossRefPubMed

32.

Ettehad D, Emdin CA, Kiran A, Anderson SG, Callender T, Emberson J, et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet. 2016;387(10022):957–67. https://doi.org/10.1016/s0140-6736(15)01225-8.CrossRefPubMed

33.

Virani SS, Newby LK, Arnold SV, Bittner V, Brewer LC, Demeter SH, et al. 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the management of patients with chronic coronary disease: a report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice guidelines. Circulation. 2023;148(9):e9–119. https://doi.org/10.1161/CIR.0000000000001168.CrossRefPubMed

34.

Twiner MJ, Hennessy J, Wein R, Levy PD. Nitroglycerin use in the Emergency Department: current perspectives. Open Access Emerg Med. 2022;14:327–33. https://doi.org/10.2147/oaem.S340513.CrossRefPubMedPubMedCentral

35.

Wei DY, Goadsby PJ. Comprehensive clinical phenotyping of nitroglycerin infusion induced cluster headache attacks. Cephalalgia: Int J Headache. 2021;41(8):913–33. https://doi.org/10.1177/0333102421989617.CrossRef

36.

May A, Bahra A, Buchel C, Frackowiak RS, Goadsby PJ. Hypothalamic activation in cluster headache attacks. Lancet. 1998;352(9124):275–8. https://doi.org/10.1016/S0140-6736(98)02470-2.CrossRefPubMed

37.

Khouri C, Blaise S, Carpentier P, Villier C, Cracowski JL, Roustit M. Drug-induced Raynaud’s phenomenon: beyond β-adrenoceptor blockers. Br J Clin Pharmacol. 2016;82(1):6–16. https://doi.org/10.1111/bcp.12912.CrossRefPubMedPubMedCentral

38.

Gérard AO, Merino D, Van Obberghen EK, Rocher F, Destere A, Lantéri-Minet M, et al. Calcitonin gene-related peptide-targeting drugs and Raynaud’s phenomenon: a real-world potential safety signal from the WHO pharmacovigilance database. J Headache Pain. 2022;23(1):53. https://doi.org/10.1186/s10194-022-01424-w.CrossRefPubMedPubMedCentral

39.

Evans RW. Raynaud’s Phenomenon Associated with calcitonin gene-related peptide monoclonal antibody antagonists. Headache. 2019;59(8):1360–4. https://doi.org/10.1111/head.13596.CrossRefPubMed

40.

Breen ID, Brumfiel CM, Patel MH, Butterfield RJ, VanderPluym JH, Griffing L, et al. Evaluation of the safety of calcitonin gene-related peptide antagonists for Migraine Treatment among adults with Raynaud Phenomenon. JAMA Netw Open. 2021;4(4):e217934. https://doi.org/10.1001/jamanetworkopen.2021.7934.CrossRefPubMedPubMedCentral

41.

Rirash F, Tingey PC, Harding SE, Maxwell LJ, Tanjong Ghogomu E, Wells GA, et al. Calcium channel blockers for primary and secondary Raynaud’s phenomenon. Cochrane Database Syst Rev. 2017;12(12):Cd000467. https://doi.org/10.1002/14651858.CD000467.pub2.CrossRefPubMed

42.

Ohlsson L, Kronvall E, Stratton J, Edvinsson L. Fremanezumab blocks CGRP induced dilatation in human cerebral, middle meningeal and abdominal arteries. J Headache Pain. 2018;19(1):66. https://doi.org/10.1186/s10194-018-0905-8.CrossRefPubMedPubMedCentral

43.

Mulder IA, Li M, de Vries T, Qin T, Yanagisawa T, Sugimoto K, et al. Anti-migraine calcitonin gene-related peptide receptor antagonists worsen cerebral ischemic outcome in mice. Ann Neurol. 2020;88(4):771–84. https://doi.org/10.1002/ana.25831.CrossRefPubMedPubMedCentral

44.

de Boer I, MaassenVanDenBrink A, Terwindt GM. The potential danger of blocking CGRP for treating migraine in CADASIL patients. Cephalalgia: Int J Headache. 2020;40(14):1676–8. https://doi.org/10.1177/0333102420941814.CrossRef

45.

Baron EP. Headache, cerebral aneurysms, and the use of triptans and ergot derivatives. Headache. 2015;55(5):739–47. https://doi.org/10.1111/head.12562.CrossRefPubMed

46.

Roberto G, Piccinni C, D’Alessandro R, Poluzzi E. Triptans and serious adverse vascular events: data mining of the FDA adverse event reporting System database. Cephalalgia: Int J Headache. 2014;34(1):5–13. https://doi.org/10.1177/0333102413499649.CrossRef

47.

Henkes H, May A, Kühne D, Berg-Dammer E, Diener HC. Sumatriptan: vasoactive effect on human dural vessels, demonstrated by subselective angiography. Cephalalgia: Int J Headache. 1996;16(4):224–30. https://doi.org/10.1046/j.1468-2982.1996.1604224.x.CrossRef

48.

Cittadini E, Matharu MS. Symptomatic trigeminal autonomic cephalalgias. Neurologist; 2009. pp. 305–12.

49.

de Coo IF, Wilbrink LA, Haan J. Symptomatic trigeminal autonomic Cephalalgias. Current pain and headache reports. 2015;19(8):39. https://doi.org/10.1007/s11916-015-0514-z.

50.

Chowdhury D, Secondary. (Symptomatic) trigeminal autonomic Cephalalgia. Ann Indian Acad Neurol. 2018;21(Suppl 1):S57–69. https://doi.org/10.4103/aian.AIAN_16_18.CrossRefPubMedPubMedCentral

51.

Hakim SM. Warfarin for refractory chronic cluster headache: a randomized pilot study. Headache. 2011;51(5):713–25. https://doi.org/10.1111/j.1526-4610.2011.01856.x.CrossRefPubMed

52.

Schindler EAD, Cooper V, Quine DB, Fenton BT, Wright DA, Weil MJ, et al. You will eat shoe Polish if you think it would help-Familiar and lesser-known themes identified from mixed-methods analysis of a cluster headache survey. Headache. 2021. https://doi.org/10.1111/head.14063.CrossRefPubMed

53.

Torelli P, Manzoni GC. Behavior during cluster headache. Curr Pain Headache Rep. 2005;9(2):113–9.CrossRefPubMed

54.

Noseda R, Bedussi F, Gobbi C, Ceschi A, Zecca C. Safety profile of monoclonal antibodies targeting the calcitonin gene-related peptide system in pregnancy: updated analysis in VigiBase^®. Cephalalgia: Int J Headache. 2023;43(4):3331024231158083. https://doi.org/10.1177/03331024231158083.

55.

Taylor FR. Antigens and antibodies in Disease with Specifics about CGRP Immunology. Headache. 2018;58(Suppl 3):230–7. https://doi.org/10.1111/head.13409.CrossRefPubMed

56.

Simister NE. Placental transport of immunoglobulin G. Vaccine. 2003;21(24):3365–9. https://doi.org/10.1016/s0264-410x(03)00334-7.CrossRefPubMed

57.

VanderPluym J. Cluster headache: special considerations for treatment of female patients of Reproductive Age and Pediatric patients. Curr Neurol Neurosci Rep. 2016;16(1):5. https://doi.org/10.1007/s11910-015-0610-9.CrossRefPubMed

58.

Jrgens TP, Schaefer C, May A. Treatment of cluster headache in pregnancy and lactation. Cephalalgia: Int J Headache. 2009;29(4):391–400.CrossRef

59.

Schindler EAD, Cooper V, Quine DB, Fenton BT, Wright DA, Weil MJ, et al. You will eat shoe Polish if you think it would help-Familiar and lesser-known themes identified from mixed-methods analysis of a cluster headache survey. Headache. 2021;61(2):318–28. https://doi.org/10.1111/head.14063.CrossRefPubMed

60.

Leone M, D’Amico D, Moschiano F, Fraschini F, Bussone G. Melatonin versus placebo in the prophylaxis of cluster headache: a double-blind pilot study with parallel groups. Cephalalgia: Int J Headache. 1996;16(7):494–6.CrossRef

61.

Ludemann P, Frese A, Happe S, Evers S. Sleep disordered breathing in patients with cluster headache. Neurology. 2001;56(7):984.CrossRefPubMed

62.

Robbins MS. The psychiatric comorbidities of cluster headache. Curr Pain Headache Rep. 2013;17(2):313. https://doi.org/10.1007/s11916-012-0313-8.CrossRefPubMed

63.

Costa A, Leston JA, Cavallini A, Nappi G. Cluster headache and periodic affective illness: common chronobiological features. Funct Neurol. 1998;13(3):263–72.PubMed

64.

Mekler G, Woggon B. A case of serotonin syndrome caused by venlafaxine and lithium. Pharmacopsychiatry. 1997;30(6):272–3. https://doi.org/10.1055/s-2007-979507.CrossRefPubMed

65.

Adan-Manes J, Novalbos J, Lopez-Rodriguez R, Ayuso-Mateos JL, Abad-Santos F. Lithium and venlafaxine interaction: a case of serotonin syndrome. J Clin Pharm Ther. 2006;31(4):397–400. https://doi.org/10.1111/j.1365-2710.2006.00745.x.CrossRefPubMed

66.

Prakash P S, Adroja B, Parekh H. Serotonin syndrome in patients with headache disorders. BMJ Case Rep. 2017;2017. https://doi.org/10.1136/bcr-2017-221383.

67.

Wenzel RG, Tepper S, Korab WE, Freitag F. Serotonin syndrome risks when combining SSRI/SNRI drugs and triptans: is the FDA’s alert warranted? Ann Pharmacother. 2008;42(11):1692–6. https://doi.org/10.1345/aph.1L260.CrossRefPubMed

68.

Orlova Y, Rizzoli P, Loder E. Association of Coprescription of Triptan Antimigraine Drugs and selective serotonin reuptake inhibitor or selective norepinephrine reuptake inhibitor antidepressants with serotonin syndrome. JAMA Neurol. 2018;75(5):566–72. https://doi.org/10.1001/jamaneurol.2017.5144.CrossRefPubMedPubMedCentral

69.

Lorefice L, Fenu G, Fois M, Frau J, Coghe G, Marrosu MG, et al. Pulse steroid therapy in multiple sclerosis and mood changes: an exploratory prospective study. Mult Scler Relat Disord. 2018;20:104–8. https://doi.org/10.1016/j.msard.2018.01.012.CrossRefPubMed

70.

Naber D, Sand P, Heigl B. Psychopathological and neuropsychological effects of 8-days’ corticosteroid treatment. A prospective study. Psychoneuroendocrinology. 1996;21(1):25–31. https://doi.org/10.1016/0306-4530(95)00031-3.CrossRefPubMed

71.

Lewis DA, Smith RE. Steroid-induced psychiatric syndromes. A report of 14 cases and a review of the literature. J Affect Disord. 1983;5(4):319–32. https://doi.org/10.1016/0165-0327(83)90022-8.CrossRefPubMed

72.

Rozen TD, Fishman RS. Cluster headache in the United States of America: demographics, clinical characteristics, triggers, suicidality, and personal burden. Headache. 2012;52(1):99–113. https://doi.org/10.1111/j.1526-4610.2011.02028.x.CrossRefPubMed

73.

Ji Lee M, Cho SJ, Wook Park J, Kyung Chu M, Moon HS, Chung PW, et al. Increased suicidality in patients with cluster headache. Cephalalgia: Int J Headache. 2019;39(10):1249–56. https://doi.org/10.1177/0333102419845660.CrossRef

74.

Syed O, Jancic P, Fink AB, Knezevic NN. Drug Safety and Suicidality Risk of Chronic Pain medications. Pharmaceuticals (Basel). 2023;16(10). https://doi.org/10.3390/ph16101497.

75.

Fardet L, Petersen I, Nazareth I. Suicidal behavior and severe neuropsychiatric disorders following glucocorticoid therapy in primary care. Am J Psychiatry. 2012;169(5):491–7. https://doi.org/10.1176/appi.ajp.2011.11071009.CrossRefPubMed

76.

Judd LL, Schettler PJ, Brown ES, Wolkowitz OM, Sternberg EM, Bender BG, et al. Adverse consequences of glucocorticoid medication: psychological, cognitive, and behavioral effects. Am J Psychiatry. 2014;171(10):1045–51. https://doi.org/10.1176/appi.ajp.2014.13091264.CrossRefPubMed

77.

Manitpisitkul P, Curtin CR, Shalayda K, Wang SS, Ford L, Heald D. Pharmacokinetic interactions between topiramate and diltiazem, hydrochlorothiazide, or propranolol. Clin Pharmacol Drug Dev. 2014;3(5):378–87. https://doi.org/10.1002/cpdd.107.CrossRefPubMed

78.

Bialer M, Doose DR, Murthy B, Curtin C, Wang SS, Twyman RE, et al. Pharmacokinetic interactions of topiramate. Clin Pharmacokinet. 2004;43(12):763–80. https://doi.org/10.2165/00003088-200443120-00001.CrossRefPubMed

79.

2024. https://www.micromedexsolutions.com.

80.

2024. http://online.lexi.com/.

81.

Belyaeva II, Subbotina AG, Eremenko II, Tarasov VV, Chubarev VN, Schioth HB, et al. Pharmacogenetics in primary Headache disorders. Front Pharmacol. 2021;12:820214. https://doi.org/10.3389/fphar.2021.820214.CrossRefPubMed

82.

Jain R, Kumar H, Tawhai M, Douglas R. The impact of endoscopic sinus surgery on paranasal physiology in simulated sinus cavities. Int Forum Allergy Rhinol. 2017;7(3):248–55. https://doi.org/10.1002/alr.21879.CrossRefPubMed

83.

Nabi S, Rotenberg BW, Vukin I, Payton K, Bureau Y. Nasal spray adherence after sinus surgery: problems and predictors. J Otolaryngol Head Neck Surg. 2012;41(Suppl 1):S49–55.PubMed

84.

Oude Nijhuis JC, Haane DY, Koehler PJ. A review of the current and potential oxygen delivery systems and techniques utilized in cluster headache attacks. Cephalalgia: Int J Headache. 2016;36(10):970–9. https://doi.org/10.1177/0333102415616878.CrossRef

85.

Robbins MS. Clinic-based procedures for Headache. Continuum (Minneap Minn). 2021;27(3):732–45. https://doi.org/10.1212/CON.0000000000000959.CrossRefPubMed

86.

Jasper JF, Hayek SM. Implanted occipital nerve stimulators. Pain Physician. 2008;11(2):187–200.CrossRefPubMed

87.

Wilbrink LA, de Coo IF, Doesborg PGG, Mulleners WM, Teernstra OPM, Bartels EC, et al. Safety and efficacy of occipital nerve stimulation for attack prevention in medically intractable chronic cluster headache (ICON): a randomised, double-blind, multicentre, phase 3, electrical dose-controlled trial. Lancet Neurol. 2021;20(7):515–25. https://doi.org/10.1016/S1474-4422(21)00101-0.CrossRefPubMed

88.

Nowacki A, Schober M, Nader L, Saryyeva A, Nguyen TK, Green AL, et al. Deep brain stimulation for chronic cluster headache: Meta-Analysis of Individual Patient Data. Ann Neurol. 2020;88(5):956–69. https://doi.org/10.1002/ana.25887.CrossRefPubMed

89.

Schoenen J, Jensen RH, Lanteri-Minet M, Lainez MJ, Gaul C, Goodman AM, et al. Stimulation of the sphenopalatine ganglion (SPG) for cluster headache treatment. Pathway CH-1: a randomized, sham-controlled study. Cephalalgia: Int J Headache. 2013;33(10):816–30. https://doi.org/10.1177/0333102412473667.CrossRef

90.

Kimbrell V. Elements of effective patient screening to Improve Safety in MRI. Magn Reson Imaging Clin N Am. 2020;28(4):489–96. https://doi.org/10.1016/j.mric.2020.07.005.CrossRefPubMed

91.

Schindler EA, Gottschalk CH, Weil MJ, Shapiro RE, Wright DA, Sewell RA. Indoleamine Hallucinogens in Cluster Headache: results of the clusterbusters Medication Use Survey. J Psychoactive Drugs. 2015;47(5):372–81. https://doi.org/10.1080/02791072.2015.1107664.CrossRefPubMed

92.

Rozen TD, Fishman RS. Inhaled oxygen and cluster headache sufferers in the United States: use, efficacy and economics: results from the United States. Cluster Headache Surv Headache. 2011;51(2):191–200. https://doi.org/10.1111/j.1526-4610.2010.01806.x.CrossRef

93.

Cluster O2 Kit. https://www.clusterheadaches.com/ccp8/index.php?app=ecom&ns=prodshow&ref=clustero2kit (2024). Accessed.

94.

Rozen TD, Fishman RS. Demand valve oxygen: a promising new oxygen delivery system for the acute treatment of cluster headache. Pain Med. 2013;14(4):455–9. https://doi.org/10.1111/pme.12055.CrossRefPubMed

95.

Sewell RA, Halpern JH, Pope HG Jr. Response of cluster headache to psilocybin and LSD. Neurology. 2006;66(12):1920–2. https://doi.org/10.1212/01.wnl.0000219761.05466.43.CrossRefPubMed

96.

Schindler EAD, Sewell RA, Gottschalk CH, Luddy C, Flynn LT, Zhu Y, et al. Exploratory investigation of a patient-informed low-dose psilocybin pulse regimen in the suppression of cluster headache: results from a randomized, double-blind, placebo-controlled trial. Headache. 2022;62(10):1383–94. https://doi.org/10.1111/head.14420.CrossRefPubMed

97.

Schindler EAD, Sewell RA, Gottschalk CH, Flynn LT, Zhu Y, Pittman BP, et al. Psilocybin pulse regimen reduces cluster headache attack frequency in the blinded extension phase of a randomized controlled trial. J Neurol Sci. 2024;460:122993. https://doi.org/10.1016/j.jns.2024.122993.CrossRefPubMed

98.

Madsen MK, Petersen AS, Stenbaek DS, Sorensen IM, Schionning H, Fjeld T, et al. CCH attack frequency reduction after psilocybin correlates with hypothalamic functional connectivity. Headache. 2024;64(1):55–67. https://doi.org/10.1111/head.14656.CrossRefPubMed

99.

Lionetto L, Negro A, Casolla B, Simmaco M, Martelletti P. Sumatriptan succinate: pharmacokinetics of different formulations in clinical practice. Expert Opin Pharmacother. 2012;13(16):2369–80. https://doi.org/10.1517/14656566.2012.730041.CrossRefPubMed

Title: Managing Cluster Headache in Patients with Medical, Psychiatric, and Surgical Comorbidities
Authors: Mark J. Burish
Alexander B. Guirguis
Emmanuelle A. D. Schindler
Publication date: 17-07-2024
Publisher: Springer US
Keywords: Cluster Headache
Triptan Drugs
Verapamil
Galcanezumab
Topiramate
Published in: Current Neurology and Neuroscience Reports / Issue 9/2024
Print ISSN: 1528-4042
Electronic ISSN: 1534-6293
DOI: https://doi.org/10.1007/s11910-024-01362-x

CGRP Modulating Therapies: An Update

Migraine
Review

Discontinuing DMTs in multiple sclerosis

Multiple Sclerosis
Review

Patient-Centered Management of Brain Tumor-Related Epilepsy

Epilepsy
Review

Migraine management in medically complex patients

Migraine
Review

Code-ICH: A New Paradigm for Emergency Intervention

Hematoma
Review

Improving Quality of Care for Status Epilepticus: Putting Protocols into Practice

Status Epilepticus
Review

How can you integrate PET into your practice? (Link opens in a new window)

Alzheimer Disease
Independent Medical Education

PET imaging is playing an increasingly critical role in managing AD. Our expert-led program will empower you with practical strategies and real-world case studies to effectively integrate it into clinical practice.

This content is intended for healthcare professionals outside of the UK.

Supported by:

Lilly

Developed by: Springer Healthcare IME

Keynote series | Spotlight on menopause

Menopause
Video Series

Menopause can have a significant impact on the body, with effects ranging beyond the endocrine and reproductive systems. Learn about the systemic effects of menopause, so you can help patients in your clinics through the transition.

Prof. Martha Hickey

Dr. Claudia Barth

Dr. Samar El Khoudary

Developed by: Springer Medicine

Watch now

Keynote series | Spotlight on managing health in obesity

Springer Medicine

Managing Cluster Headache in Patients with Medical, Psychiatric, and Surgical Comorbidities

Abstract

Purpose of Review

Recent Findings

Summary

Other articles of this Issue 9/2024

CGRP Modulating Therapies: An Update

Discontinuing DMTs in multiple sclerosis

Patient-Centered Management of Brain Tumor-Related Epilepsy

Migraine management in medically complex patients

Code-ICH: A New Paradigm for Emergency Intervention

Improving Quality of Care for Status Epilepticus: Putting Protocols into Practice

How can you integrate PET into your practice? (Link opens in a new window)

Keynote series | Spotlight on menopause

Keynote series | Spotlight on managing health in obesity

Springer Medicine

Abstract

Purpose of Review

Recent Findings

Summary

Please log in to get access to this content